Personally I wouldn’t place any weight on the FY23 figures for calculating P/E ratios etc, they’re ancient history given annual growth in revenues of ca100%. I think you’re better off annualising the latest quarterly figures and calculating the EV/EBITDA ratio for a measure of value. I suspect if the business was in the tech or pharmaceuticals industries, its current data would result in a far higher share price. And yet the healthcare supplements industry yields just as much opportunity for growth.
Personally I wouldn’t place any weight on the FY23 figures for...
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EZZ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.91 |
Change
0.010(0.53%) |
Mkt cap ! $84.82M | |||
| Open | High | Low | Value | Volume |
| $1.95 | $1.95 | $1.86 | $51.08K | 26.90K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2240 | $1.90 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.91 | 3228 | 1 |
View Market Depth
| Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
| EZZ (ASX) Chart |